It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma.
Questions
1. What have we learned so far from clinical trials of immune checkpoint inhibition for urothelial cancer? (0:06)
2. What have been the latest efficacy and safety findings of the JAVELIN Bladder 100 trial? (0:32)
3. How do the findings of this study compare with those of other immune checkpoint inhibitors in this treatment setting? (1:54)
4. How can we predict which patients are most likely to respond to avelumab? (2:57)
5. What lies ahead in the treatment of urothelial cancer? (4:42)
Speaker disclosure: Thomas Powles has received honoraria from AstraZeneca, Bristol-Myers Squibb, Ferring, GLG Group, Janssen Research & Development, MERCK, Novartis, Pfizer, Roche/Genentech and Seattle Genetics/Astellas. He has held a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Incyte, Ipsen, Merck, Novartis, Pfizer and Seattle Genetics. He has received research funding from AstraZeneca/MedImmune and Roche/Genentech and travel, accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, Ferring, MSD, Novartis/Ipsen, Pfizer, Research to Practice and Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
